🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsGLP-1/GIP receptor co-agonism — anyone have experience? Page 4

GLP-1/GIP receptor co-agonism — anyone have experience?

Dr.NephBHM_UK Thu, Apr 2, 2026 at 2:36 AM 36 replies 1,378 viewsPage 4 of 8
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Apr 4, 2026 at 4:28 AM#16

From the other side of the consultation, briefly. Start from the measurement rather than the conclusion. Almost every disagreement here turns out to be two people measuring different things and comparing the numbers anyway.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

37 12AttorneyGrant, DebRD_ATL, KristenIndy and 34 others
Reply Quote Save Share Report
rick_sfbay
Member
289
1,234
Jan 2025
San Francisco, CA
Apr 4, 2026 at 9:32 AM#17

Following on from tony_orlando — and this may be the naive question:

Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?

36 11NicoleRaleigh, james_edin, FranDenver and 33 others
Reply Quote Save Share Report
Dr.DermMIA
Member
456
2,123
May 2024
Miami, FL
Apr 4, 2026 at 2:36 PM#18
Dr.Martinez said:
Start from the measurement rather than the conclusion.

I read this differently from Dr.Martinez, on substance rather than tone. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.

Last edited: Apr 4, 2026 at 4:36 PM
35 10A1cHero_PHX, Dr.RenalNash, LipidDoc_ATL and 32 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Apr 4, 2026 at 7:41 PM#19
Dr.Martinez said:
Start from the measurement rather than the conclusion.

Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Last edited: Apr 5, 2026 at 1:41 AM
34 9stefan_berlin, Dr.EM_Chicago, pete_RVA and 31 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Apr 5, 2026 at 12:46 AM#20

Moderator note: the sourcing question belongs in the vendor section and has been split out. Tagging this one for the weekly digest.

Last edited: Apr 5, 2026 at 2:46 AM
12 12PurityPaulOR, MaxMetOK, MounjBrad and 9 others
Reply Quote Save Share Report

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register